Spots Global Cancer Trial Database for A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Official Title: A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Study ID: NCT03999684

Conditions

Adenoid Cystic Carcinoma

Interventions

Tretinoin

Study Description

Brief Summary: This research is studying how safe and effective all-trans retinoic acid (ATRA), is to treat advanced adenoid cystic carcinoma (ACC).

Detailed Description: This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved all-trans retinoic acid (ATRA) for this specific disease but it has been approved for other uses. The main purpose of this study is to see how effective all-trans retinoic acid (ATRA) is in treating tumor. Other reasons for conducting the study are: * To determine for how long all-trans retinoic acid (ATRA) may reduce the size or slow down the growth of tumor * To evaluate levels of circulating tumor DNA (ctDNA) released in the bloodstream as an indication of the disease activity * To better understand mechanisms of tumor resistance to ATRA